Trends in Precision Medicine

Precision medicine (PM) can be defined as an approach toward prevention and treatment of disease by development of diagnostics and therapies delivering maximum effectiveness by considering individual gene variability, integrating clinical and molecular information and factors like environment and lifestyle. PM has already delivered success in targeted therapies for cancer and cystic fibrosis in patients having the common casual genotypes. Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information. In the era of PM, deep phenotyping is done using detailed and precise examination of disease and integration of this data with genomic variation and clinical information. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure maximal efficacy and safety of treatment. The major hindrance toward the development of such therapies is the handling of the “Big Data,” to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases.

[1]  Diego Martínez Hernández,et al.  Automated semantic annotation of rare disease cases: a case study , 2014, Database J. Biol. Databases Curation.

[2]  P. Hammond,et al.  Large‐scale objective phenotyping of 3D facial morphology , 2012, Human mutation.

[3]  I. Kwon,et al.  Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Alejandro Sifrim,et al.  Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data , 2015, The Lancet.

[5]  Kiran Musunuru,et al.  CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo—Brief Report , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[6]  Russ B. Altman,et al.  Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text , 2009, BMC Bioinformatics.

[7]  Nigel Collier,et al.  Automatic concept recognition using the Human Phenotype Ontology reference and test suite corpora , 2015, Database J. Biol. Databases Curation.

[8]  M. Stolar Defining and achieving treatment success in patients with type 2 diabetes mellitus. , 2010, Mayo Clinic proceedings.

[9]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[10]  J Jack Lee,et al.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Engelman,et al.  Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[12]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[13]  John P. Overington,et al.  An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.

[14]  Marc Cruts,et al.  Locus-Specific Mutation Databases for Neurodegenerative Brain Diseases , 2012, Human mutation.

[15]  Dan Peer,et al.  Omics-based nanomedicine: the future of personalized oncology. , 2014, Cancer letters.

[16]  Manuel Corpas,et al.  DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. , 2009, American journal of human genetics.

[17]  K. Jain,et al.  Role of Nanobiotechnology in Developing Personalized Medicine for Cancer , 2005, Technology in cancer research & treatment.

[18]  Jennifer B. McCormick,et al.  Was it worth it? Patients’ perspectives on the perceived value of genomic-based individualized medicine , 2016, Journal of Community Genetics.

[19]  P. Robinson,et al.  Strategies for exome and genome sequence data analysis in disease‐gene discovery projects , 2011, Clinical genetics.

[20]  Ludovic C. Gillet,et al.  Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps , 2015, Nature Medicine.

[21]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[22]  S. Bowdin,et al.  The Genome Clinic: A Multidisciplinary Approach to Assessing the Opportunities and Challenges of Integrating Genomic Analysis into Clinical Care , 2014, Human mutation.

[23]  George Hripcsak,et al.  Next-generation phenotyping of electronic health records , 2012, J. Am. Medical Informatics Assoc..

[24]  Huaqin Pan,et al.  Using PhenX measures to identify opportunities for cross‐study analysis , 2012, Human mutation.

[25]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[26]  John J Rossi,et al.  RNAi and small interfering RNAs in human disease therapeutic applications. , 2010, Trends in biotechnology.

[27]  J. Lupski,et al.  From genomic medicine to precision medicine: highlights of 2015 , 2016, Genome Medicine.

[28]  C. Gieger,et al.  Human metabolic individuality in biomedical and pharmaceutical research , 2011, Nature.

[29]  S. Barlas Precision medicine initiative aims for a new generation of diagnostics and treatments: but is the promise of genetic targeting overinflated? , 2015, P & T : a peer-reviewed journal for formulary management.

[30]  Osman Ugur Sezerman,et al.  Application of Automatic Mutation-gene Pair Extraction to Diseases , 2007, J. Bioinform. Comput. Biol..

[31]  D. Peer,et al.  RNAi-based nanomedicines for targeted personalized therapy. , 2012, Advanced drug delivery reviews.

[32]  J. Shendure,et al.  Exome sequencing as a tool for Mendelian disease gene discovery , 2011, Nature Reviews Genetics.

[33]  John M. Hancock,et al.  Entity/quality-based logical definitions for the human skeletal phenome using PATO , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[34]  Monte Westerfield,et al.  Linking Human Diseases to Animal Models Using Ontology-Based Phenotype Annotation , 2009, PLoS biology.

[35]  D. Roden,et al.  The Emerging Role of Electronic Medical Records in Pharmacogenomics , 2011, Clinical pharmacology and therapeutics.

[36]  M. Dolsten,et al.  Precision medicine: an approach to R&D for delivering superior medicines to patients , 2012, Clinical and Translational Medicine.

[37]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[38]  James J. Chen,et al.  Pharmacogenomic biomarkers for personalized medicine. , 2013, Pharmacogenomics.

[39]  F. Gueyffier,et al.  Recherche translationnelle : médecine personnalisée, médecine de précision, thérapies ciblées : marketing ou science ? , 2015 .

[40]  Ryan Hendricks,et al.  The landscape of precision cancer medicine clinical trials in the United States. , 2015, Cancer treatment reviews.

[41]  David E. Fisher,et al.  Precision medicine for cancer with next-generation functional diagnostics , 2015, Nature Reviews Cancer.

[42]  R. Hennekam,et al.  Elements of morphology: Introduction , 2009, American journal of medical genetics. Part A.

[43]  F. Collins,et al.  The Human Genome Project: Lessons from Large-Scale Biology , 2003, Science.

[44]  John M. Hancock,et al.  Integration of global resources for human genetic variation and disease , 2012, Human mutation.

[45]  R. Barrangou,et al.  CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.

[46]  Damian Smedley,et al.  Construction and accessibility of a cross-species phenotype ontology along with gene annotations for biomedical research , 2013, F1000Research.

[47]  Rui Chen,et al.  Promise of personalized omics to precision medicine , 2013, Wiley interdisciplinary reviews. Systems biology and medicine.

[48]  Monte Westerfield,et al.  ZFIN, the Zebrafish Model Organism Database: increased support for mutants and transgenics , 2012, Nucleic Acids Res..

[49]  G. Nolan,et al.  Cloud and heterogeneous computing solutions exist today for the emerging big data problems in biology , 2011, Nature Reviews Genetics.

[50]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[51]  M. Buck,et al.  Obesity and Ovarian Cancer Survival: A Systematic Review and Meta-analysis , 2012, Cancer Prevention Research.

[52]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[53]  Pedro G. Ferreira,et al.  Transcriptome and genome sequencing uncovers functional variation in humans , 2013, Nature.

[54]  D. Eizirik,et al.  Candidate genes for type 1 diabetes modulate pancreatic islet inflammation and β‐cell apoptosis , 2013, Diabetes, obesity & metabolism.

[55]  Pierre Grenon,et al.  ApiNATOMY: A novel toolkit for visualizing multiscale anatomy schematics with phenotype‐related information , 2012, Human mutation.

[56]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[57]  R. Ahima Editorial: Rethinking the definition of diabetes for precision medicine. , 2015, Molecular endocrinology.

[58]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[59]  B. V. van Bon,et al.  Diagnostic exome sequencing in persons with severe intellectual disability. , 2012, The New England journal of medicine.

[60]  Benjamin J. Raphael,et al.  Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine , 2014, Genome Medicine.

[61]  Samantha A. Adams,et al.  Precision medicine: opportunities, possibilities, and challenges for patients and providers , 2016, J. Am. Medical Informatics Assoc..

[62]  David C Whitcomb,et al.  Evolving Roles for Physicians and Genetic Counselors in Managing Complex Genetic Disorders , 2015, Clinical and Translational Gastroenterology.

[63]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[64]  Cathryn M. Delude Deep phenotyping: The details of disease , 2015, Nature.

[65]  L. Liang,et al.  Mapping complex disease traits with global gene expression , 2009, Nature Reviews Genetics.

[66]  Mechanistic insights revealed by lipid profiling in monogenic insulin resistance syndromes , 2015, Genome Medicine.

[67]  Tudor Groza,et al.  Phenotyping: Targeting genotype's rich cousin for diagnosis , 2014, Journal of paediatrics and child health.

[68]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[69]  Darin P Clark,et al.  Whole-animal imaging, gene function, and the Zebrafish Phenome Project. , 2011, Current opinion in genetics & development.

[70]  Michael Brudno,et al.  PhenoTips: Patient Phenotyping Software for Clinical and Research Use , 2013, Human mutation.

[71]  B. Knoppers,et al.  The ethical framing of personalized medicine , 2014, Current opinion in allergy and clinical immunology.

[72]  Thomas A. Peterson,et al.  Towards precision medicine: advances in computational approaches for the analysis of human variants. , 2013, Journal of molecular biology.

[73]  Mark I McCarthy,et al.  Genomics, type 2 diabetes, and obesity. , 2010, The New England journal of medicine.

[74]  Absar Ahmad,et al.  Association of Genetic polymorphism of PPARγ-2, ACE, MTHFR, FABP-2 and FTO genes in risk prediction of type 2 diabetes mellitus , 2013, Journal of Biomedical Science.

[75]  A. Giordano,et al.  A Commentary on iPS Cells: Potential Applications in Autologous Transplantation, Study of Illnesses and Drug Screening , 2014, Journal of cellular physiology.

[76]  D. Valle,et al.  PhenoDB: A New Web-Based Tool for the Collection, Storage, and Analysis of Phenotypic Features , 2013, Human mutation.

[77]  W. Cefalu,et al.  The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action! , 2014, Diabetes Care.

[78]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[79]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[80]  Jun Liu,et al.  Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy , 2013, Journal of Neuroimmune Pharmacology.

[81]  Ian McGonigle The collective nature of personalized medicine. , 2016, Genetics research.

[82]  K. O'Byrne,et al.  The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC , 2011, Journal of Clinical Pathology.

[83]  Dan Peer,et al.  Reshaping the future of nanopharmaceuticals: ad iudicium. , 2011, ACS nano.

[84]  Jennifer B. McCormick,et al.  Patients' views on incidental findings from clinical exome sequencing , 2015, Applied & translational genomics.

[85]  Fred E. Cohen,et al.  Automated extraction of mutation data from the literature: application of MuteXt to G protein-coupled receptors and nuclear hormone receptors , 2004, Bioinform..

[86]  Kwangmeyung Kim,et al.  Theranostic gas-generating nanoparticles for targeted ultrasound imaging and treatment of neuroblastoma. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[87]  Adam D. Kennedy,et al.  Sharpening Precision Medicine by a Thorough Interrogation of Metabolic Individuality , 2016, Computational and structural biotechnology journal.

[88]  Christian Gilissen,et al.  Disease gene identification strategies for exome sequencing , 2012, European Journal of Human Genetics.

[89]  R. Semple,et al.  Next generation sequencing--implications for clinical practice. , 2011, British medical bulletin.

[90]  D. Bick,et al.  Whole Exome and Whole Genome Sequencing – Community Plan Medical Policy , 2018 .

[91]  M. Fedorova,et al.  Identification of carbonylated lipids from different phospholipid classes by shotgun and LC-MS lipidomics , 2015, Analytical and Bioanalytical Chemistry.

[92]  Rajagopal N. Aravalli,et al.  Gene editing technology as an approach to the treatment of liver diseases , 2016, Expert opinion on biological therapy.

[93]  J. Denny,et al.  Extracting research-quality phenotypes from electronic health records to support precision medicine , 2015, Genome Medicine.

[94]  D. Haussecker,et al.  The Business of RNAi Therapeutics in 2012 , 2012, Molecular therapy. Nucleic acids.

[95]  K. Jain Innovative Diagnostic Technologies and Their Significance for Personalized Medicine , 2010, Molecular Diagnosis & Therapy.

[96]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[97]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[98]  David J. Arenillas,et al.  GeneYenta: A Phenotype­Based Rare Disease Case Matching Tool Based on Online Dating Algorithms for the Acceleration of Exome Interpretation , 2015, Human mutation.

[99]  D. Koller,et al.  Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals , 2013, Genome research.

[100]  Judith A. Blake,et al.  The Mouse Genome Database: integration of and access to knowledge about the laboratory mouse , 2013, Nucleic Acids Res..

[101]  Mark E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[102]  Chao Pang,et al.  Observ‐OM and Observ‐TAB: Universal syntax solutions for the integration, search, and exchange of phenotype and genotype information , 2012, Human mutation.

[103]  Caleb Webber,et al.  Phenotype Ontologies and Cross-Species Analysis for Translational Research , 2014, PLoS genetics.

[104]  L. Marraffini,et al.  CRISPR Interference Limits Horizontal Gene Transfer in Staphylococci by Targeting DNA , 2008, Science.

[105]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[106]  Melanie Bahlo,et al.  Reducing the exome search space for Mendelian diseases using genetic linkage analysis of exome genotypes , 2011, Genome Biology.

[107]  M. Guyer,et al.  Charting a course for genomic medicine from base pairs to bedside , 2011, Nature.

[108]  Funda Meric-Bernstam,et al.  Building a personalized medicine infrastructure at a major cancer center. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Peter Saffrey,et al.  Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units , 2012, Science Translational Medicine.

[110]  P. Froguel,et al.  Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science? , 2015, Therapie.

[111]  D. Peer Harnessing RNAi nanomedicine for precision therapy , 2014, Molecular and Cellular Therapies.

[112]  Carol J. Bult,et al.  Mouse Phenome Database (MPD) , 2011, Nucleic Acids Res..

[113]  Deanna M. Church,et al.  ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..

[114]  Arul M Chinnaiyan,et al.  Translating genomics for precision cancer medicine. , 2014, Annual review of genomics and human genetics.

[115]  G. Casari,et al.  Automatic extraction of mutations from Medline and cross-validation with OMIM. , 2004, Nucleic acids research.

[116]  Silvia Licoccia,et al.  Cerium oxide nanoparticles protect cardiac progenitor cells from oxidative stress. , 2012, ACS nano.

[117]  K. J. Johansen Taber,et al.  The promise and challenges of next-generation genome sequencing for clinical care. , 2014, JAMA internal medicine.

[118]  P. Donnelly,et al.  Designing Genome-Wide Association Studies: Sample Size, Power, Imputation, and the Choice of Genotyping Chip , 2009, PLoS genetics.

[119]  Leslie G Biesecker,et al.  Standard terminology for phenotypic variations: The Elements of Morphology project, its current progress, and future directions , 2012, Human mutation.

[120]  Y. Moreau,et al.  Computational tools for prioritizing candidate genes: boosting disease gene discovery , 2012, Nature Reviews Genetics.

[121]  A. Singleton,et al.  Genetic variability in the regulation of gene expression in ten regions of the human brain , 2014, Nature Neuroscience.

[122]  J. Shih,et al.  Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. , 2012, The Lancet. Oncology.

[123]  Krishanu Saha,et al.  Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.

[124]  Mark A. Rubin,et al.  Health: Make precision medicine work for cancer care , 2015, Nature.

[125]  Joshua C. Johnson,et al.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study , 2010, The Lancet.

[126]  Henrik,et al.  Association analyses of 249,796 individuals reveal eighteen new loci associated with body mass index , 2012 .

[127]  P. Robinson,et al.  The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. , 2008, American journal of human genetics.

[128]  Kaanan P. Shah,et al.  A gene-based association method for mapping traits using reference transcriptome data , 2015, Nature Genetics.

[129]  R. Kurzrock,et al.  Cancer: the road to Amiens. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  Melissa Haendel,et al.  Capturing phenotypes for precision medicine , 2015, Cold Spring Harbor molecular case studies.

[131]  C. Sabatti,et al.  The Human Phenome Project , 2003, Nature Genetics.

[132]  Satoshi Nakanishi,et al.  National BioResource Project-Rat and related activities. , 2009, Experimental animals.

[133]  Manuel L Gonzalez-Garay,et al.  Plasma metabolomic profiles enhance precision medicine for volunteers of normal health , 2015, Proceedings of the National Academy of Sciences.

[134]  Damian Smedley,et al.  Walking the interactome for candidate prioritization in exome sequencing studies of Mendelian diseases , 2014, Bioinform..

[135]  Peter N. Robinson,et al.  Deep phenotyping for precision medicine , 2012, Human mutation.

[136]  Scott A. Rifkin,et al.  Revealing the architecture of gene regulation: the promise of eQTL studies. , 2008, Trends in genetics : TIG.

[137]  Olivier Bodenreider,et al.  Toward an automatic method for extracting cancer- and other disease-related point mutations from the biomedical literature , 2011, Bioinform..